Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
DIETHYLSTILBESTROL vs LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; levonorgestrel alters cervical mucus and endometrial lining to prevent fertilization and implantation.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
One tablet containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol (or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo or ethinyl estradiol 0.01 mg alone. For extended-cycle regimens, dosing may be continuous for up to 84 days.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Levonorgestrel: ~25 hours; Ethinyl estradiol: ~13 hours. Steady-state achieved within 5-7 days; clinical efficacy maintained by daily dosing.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Levonorgestrel: 45% renal, 32% fecal; Ethinyl estradiol: 40% renal, 60% fecal. Both undergo enterohepatic recirculation.
Category C
Category D/X
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."